HomeDalfampridineDalfampridine + Abacavir Sulfate Dolutegravir Sodium Lamivudine

Does Dalfampridine Interact with Abacavir Sulfate Dolutegravir Sodium Lamivudine?

Dalfampridine and Abacavir Sulfate Dolutegravir Sodium Lamivudine have a contraindicated drug interaction according to U.S. FDA drug labeling data. Dolutegravir inhibits OCT2 and potentially MATE1, may increase plasma concentrations of dalfampridine. The mechanism involves inhibition of organic cation transporter (oct)2 and multidrug and toxin extrusion transporter (mate)1. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Contraindicated
Dalfampridine Class
Potassium Channel Blocker
Abacavir Sulfate Dolutegravir Sodium Lamivudine Class
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Management
Do not take together
Data Source
U.S. FDA via OpenFDA

How This Interaction Works

The interaction between Dalfampridine and Abacavir Sulfate Dolutegravir Sodium Lamivudine occurs because inhibition of organic cation transporter (oct)2 and multidrug and toxin extrusion transporter (mate)1. Clinically, this means dolutegravir inhibits oct2 and potentially mate1, may increase plasma concentrations of dalfampridine. Because of the severity of this interaction, these medications are contraindicated — meaning they should not be taken together under any circumstances. If you are currently taking both, contact your healthcare provider immediately to discuss alternatives.

What To Tell Your Doctor or Pharmacist

If you are taking Dalfampridine and your doctor is considering prescribing Abacavir Sulfate Dolutegravir Sodium Lamivudine (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask about alternative medications that do not interact with your current regimen
  • Ask how frequently you should be monitored while these are co-prescribed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Dalfampridine(Dalfampridine)+💊 Abacavir Sulfate Dolutegravir Sodium Lamivudine(Triumeq)

Severity & Interaction Details

contraindicated
Avoid this combination
FDA labeling lists this pair as contraindicated. The risk outweighs the benefit in nearly all cases.
Severity scale
MinorContra
On record
Yes
Drug A class
Potassium Channel Blocker
Drug B class
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Source
NLP:abacavir sulfate, dolutegravir sodium, lamivudine

What this means in plain English

Dolutegravir inhibits OCT2 and potentially MATE1, may increase plasma concentrations of dalfampridine.

What the FDA label says

"Inhibition of organic cation transporter (OCT)2 and multidrug and toxin extrusion transporter (MATE)1"

📖 Source: NLP:abacavir sulfate, dolutegravir sodium, lamivudine

Share this result:XFacebookWhatsAppReddit
Add more drugs
Check Dalfampridine and Abacavir Sulfate Dolutegravir Sodium Lamivudine against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.